| Literature DB >> 34737592 |
Weiran Xu1, Xiling Hu2, Xing Zhang3, Cong Ling4, Chaofan Wang5, Lingling Gao1.
Abstract
OBJECTIVE: This study investigated the biomedical, psychological, and social behavior risk factors for cognitive impairment in middle-aged and elderly patients with type 2 diabetes mellitus (T2DM).Entities:
Keywords: cognitive impairment; depression; self-care; social support; type 2 diabetes mellitus
Year: 2021 PMID: 34737592 PMCID: PMC8560081 DOI: 10.2147/DMSO.S333373
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Sociodemographic, Disease, Psychological, Self-Management, and Social Support Factors at Baseline Stratified by Cognitive Impairment
| Variable | Total (n=240) | Cognitive Impairment (n = 126) | No Cognitive Impairment (n = 114) | P valuea |
|---|---|---|---|---|
| N (%) | 240 | 126 (52.5) | 114 (47.5) | − |
| MoCA score | 24.72±3.64 | 21.83±2.54 | 27.92±1.10 | <0.001 |
| Age (years) | 61.15±8.15 | 63.52±8.80 | 58.54±6.47 | <0.001* |
| ~45 | 127 (52.9) | 52 (41.3) | 75 (65.8) | <0.001* |
| ~60 | 113 (47.1) | 74 (58.7) | 39 (34.2) | − |
| Sex | ||||
| Male | 155 (64.6) | 77 (61.1) | 78 (68.4) | 0.237 |
| Female | 85 (35.4) | 49 (38.9) | 36 (31.6) | − |
| Education (years) | ||||
| ≤12 | 165 (68.8) | 106 (84.1) | 59 (51.8) | <0.001* |
| >12 | 75 (31.3) | 20 (15.9) | 55 (48.2) | − |
| Place of residence | ||||
| Rural | 42 (17.5) | 37 (29.4) | 5 (4.4) | <0.001* |
| Urban | 198 (82.5) | 89 (70.6) | 109 (95.6) | − |
| Professional status | ||||
| On-job | 98 (40.8) | 41 (32.5) | 57 (50.0) | 0.006* |
| Unemployed or retired | 142 (59.2) | 85 (67.5) | 57 (50.0) | − |
| Smoking | ||||
| Yes | 90 (37.5) | 43 (34.1) | 47 (41.2) | 0.256 |
| No | 150 (62.5) | 83 (65.9) | 67 (58.8) | − |
| Drinking | ||||
| Yes | 32 (13.3) | 18 (14.3) | 14 (12.3) | 0.648 |
| No | 208 (86.7) | 108 (85.7) | 100 (87.7) | − |
| Received diabetes education | ||||
| Yes | 104 (43.4) | 51 (40.5) | 53 (46.5) | 0.348 |
| No | 136 (56.7) | 75 (59.5) | 61 (53.5) | − |
| BMI (kg/m2) | 24.57±2.68 | 24.52±2.65 | 24.61±2.73 | 0.518 |
| <18.5 | 10 (4.2) | 7 (5.6) | 3 (2.6) | 0.111 |
| ~18.5 | 95 (39.6) | 46 (36.5) | 49 (43.0) | − |
| ~24 | 110 (45.8) | 64 (50.8) | 46 (40.4) | − |
| ~28 | 25 (10.4) | 9 (7.1) | 16 (14.0) | − |
| Diabetes course (years) | 10.00 (5.00, 14.00) | 10.00 (5.00, 15.00) | 8.00 (5.00, 12.00) | 0.005* |
| <10 | 112 (46.7) | 45 (35.7) | 67 (58.8) | <0.001* |
| ≥10 | 128 (53.3) | 81 (64.3) | 47 (41.2) | − |
| Hypoglycemia in 1 month | ||||
| Yes | 60 (25.0) | 39 (31.0) | 21 (18.4) | 0.025* |
| No | 180 (75.0) | 87 (69.0) | 93 (81.6) | − |
| Diabetes treatment | ||||
| Lifestyle only | 8 (3.3) | 2 (1.6) | 6 (5.3) | 0.050 |
| Oral hypoglycemic drugs | 131 (54.6) | 63 (50.0) | 68 (59.6) | − |
| Insulin | 49 (20.4) | 33 (26.2) | 16 (14.0) | − |
| Oral hypoglycemic drugs+insulin | 52 (21.7) | 28 (22.2) | 24 (21.1) | − |
| Hypertension | ||||
| Yes | 135 (56.3) | 82 (65.1) | 53 (46.5) | 0.008 |
| No | 104 (43.4) | 43 (34.1) | 61 (53.5) | − |
| Cardiovascular disease | ||||
| Yes | 42 (17.5) | 21 (16.7) | 21 (18.4) | 0.721 |
| No | 198 (82.5) | 105 (83.3) | 93 (81.6) | − |
| Peripheral vascular disease | ||||
| Yes | 150 (62.5) | 76 (60.3) | 74 (64.9) | 0.463 |
| No | 90 (37.5) | 50 (39.7) | 40 (35.1) | − |
| Peripheral neuropathy | ||||
| Yes | 108 (45.0) | 55 (43.7) | 53 (46.5) | 0.659 |
| No | 132 (55.0) | 71 (56.3) | 61 (53.5) | − |
| Diabetic nephropathy | ||||
| Yes | 69 (28.8) | 34 (27.0) | 35 (30.7) | 0.525 |
| No | 171 (71.3) | 92 (73.0) | 79 (69.3) | − |
| Diabetic retinopathy | ||||
| Yes | 46 (19.2) | 25 (19.8) | 21 (18.4) | 0.780 |
| No | 194 (80.8) | 101 (80.2) | 93 (81.6) | − |
| HbA1c (%) ^ | 8.75±1.99 | 9.09±2.18 | 8.37±1.69 | 0.005* |
| <7 | 50 (20.8) | 22 (17.5) | 28 (24.6) | 0.176 |
| ≥7 | 190 (79.2) | 104 (82.5) | 86 (75.4) | |
| FPG (mmol/l) | 8.31±2.65 | 8.44±2.79 | 8.16±2.49 | 0.420 |
| TC (mmol/l) | 4.68±1.08 | 4.57±1.10 | 4.80±1.06 | 0.103 |
| TG (mmol/l) | 1.56 (1.11, 2.20) | 1.56 (1.02, 2.14) | 1.59 (1.17, 2.62) | 0.092 |
| HDL (mmol/l) | 1.01±0.24 | 1.03±0.27 | 1.00±0.21 | 0.436 |
| LDL (mmol/l) | 3.05±1.00 | 2.95±1.02 | 3.15±0.98 | 0.112 |
| AST (U/l) | 19.00 (17.00, 26.00) | 18.50 (16.75, 26.00) | 19.00 (17.00, 26.00) | 0.846 |
| ALT (U/l) # | 21.00 (16.00, 33.00) | 19.50 (15.00, 27.0) | 23.00 (17.00, 36.00) | 0.002* |
| ≤35 | 184 (76.7) | 101 (80.2) | 83 (72.8) | 0.179 |
| >35 | 56 (23.3) | 25 (19.8) | 31 (27.2) | |
| BUN (mmol/l) | 5.93±2.24 | 6.00±2.71 | 5.86±1.57 | 0.649 |
| Cr (μmol/l) | 70.00 (60.00, 83.00) | 71.50 (61.75, 83.50) | 66.00 (59.00, 79.00) | 0.079 |
| SDS score | 35.33±10.37 | 37.94±11.87 | 32.43±7.45 | <0.001* |
| ≥53 points | 39 (16.3) | 32 (25.4) | 7 (6.1) | <0.001* |
| <53 points | 201 (83.8) | 94 (74.6) | 107 (93.9) | |
| DSCS score | 86.66±17.79 | 79.80±17.77 | 94.24±14.48 | <0.001* |
| Exercise score | 12.68±4.95 | 11.34±4.63 | 14.16±4.90 | <0.001* |
| Diet management score | 21.05±6.02 | 20.10±6.20 | 22.11±5.65 | 0.009* |
| Medication management score | 13.90±2.28 | 13.73±2.55 | 14.09±1.93 | 0.219 |
| Blood glucose monitoring score | 9.48±3.49 | 8.21±2.84 | 10.89±3.61 | <0.001* |
| Foot care score | 17.48±5.29 | 15.52±5.61 | 19.64±3.92 | <0.001* |
| High and low blood sugar prevention and treatment score | 12.32±2.90 | 11.41±3.04 | 13.32±2.36 | <0.001* |
| SSRS score | 41.60±5.30 | 39.70±4.97 | 43.70±4.86 | <0.001* |
| Objective support score | 10.53±1.90 | 9.86±1.57 | 11.28±1.95 | <0.001* |
| Subjective support score | 24.59±3.61 | 23.44±3.66 | 25.84±3.12 | <0.001* |
| Support utilization score | 6.60±1.71 | 6.38±1.81 | 6.84±1.57 | 0.037* |
Notes: aChi-squared test for categorical variables, Student’s t-test and Mann–Whitney U-test for continuous variables; ^Targets for comprehensive control of type 2 diabetes; #Normal laboratory limit; *P < 0.05.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; DSCS, Diabetes Self-care Scale; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; MoCA, Montreal Cognitive Assessment; SDS, Self-Rating Depression Scale; SSRS, Social Support Rating Scale; TC, total cholesterol; TG, triglyceride.
Multivariate Logistic Regression Analysis of Cognitive Impairment in Patients with Type 2 Diabetes
| Variable | β | SE | Wals | OR | 95% CI | P |
|---|---|---|---|---|---|---|
| Age | 0.121 | 0.024 | 25.272 | 1.128 | 1.076–1.182 | <0.001 |
| Education >12 years | −1.325 | 0.392 | 11.435 | 0.266 | 0.123–0.573 | 0.001 |
| Living in urban area | −2.031 | 0.603 | 11.325 | 0.131 | 0.040–0.428 | 0.001 |
| Hypoglycemia in 1 month | 1.022 | 0.412 | 6.151 | 2.778 | 1.239–6.230 | 0.013 |
| Depression | 0.655 | 0.561 | 1.363 | 1.925 | 0.641–5.782 | 0.243 |
| DSCS score | −0.059 | 0.011 | 28.442 | 0.942 | 0.922–0.963 | <0.001 |
| Constant | 0.072 | 1.674 | 0.002 | 1.075 | 0.966 |
Abbreviations: CI, confidence interval; DSCS, Diabetes Self-care Scale; OR, odds ratio; SE, standard error.